About Us: Cell BioEngines, Inc., is a clinical-stage biotech company focused on curing cancer by developing 'off-the-shelf' allogenic cell therapies. The company leverages its proprietary Stem-SPACE platform technology using 'non-gene-modified' donor derived blood stem cells to produce clinical grade cells at scale. The Unmet Need: 1. Universal Blood Stem Cells: The discovery of immune cell-based therapies have transformed the treatment for blood cancer patients. Still, the process of obtaining them is from peripheral blood which is one patient - one batch limiting manufacturing scalability with high patient-to-patient variability. Moreover, complicated supply chain issues add to the hurdles of providing access to multiple patients. 2. Manufacturing Highly Potent Cells at Scale: Current cell therapies are a mixed bag of cell states or phenotypes restricting functional potency and dura- bility, particularly when providing treatments for solid cancers. Additionally, genetic modification of cells to enhance efficacy is associated with high costs. Proprietary Platform Technology: Cell BioEngines Stem-SPACE proprietary platform utilizes human umbilical cord blood stem cell as a single stable off-the-shelf source cell for all cancer therapies. The technology allows the company to expand stem cells (40X) and also differentiate them into a broad arsenal of rare, highly potent clinical-grade immune cells (2000X) for dosing 10s and 100s of patients from 1 cord blood unit at 10X lower cost. For more information, visit www.cellbioengines.com and follow us on www.twitter.com/cell_bioengines